Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) was down as much as 11.3 per cent today despite submitting a CimetrA application to the European IP Office
- The patent application was accepted by the Slovenian Intellectual Property Office (SIPO) on May 5
- MGC Pharmaca can now file subsequent applications for CimetrA in other jurisdictions such as the EU and the World Intellectual Property Organisation
- CimetrA, previously known as ArtemiC, is an immune-modulation formula that is used to treat anti-inflammatory illnesses
- MGC Pharma is now progressing towards its phase three clinical trial for CimetrA to demonstrate the full efficacy of the treatment in variants of COVID-19
- Shares in MGC Pharma are still down 11.3 per cent and are trading at 4.7 cents
MGC Pharmaceuticals (MXC) was down as much as 11.3 per cent today despite submitting a CimetrA application to the European IP Office.
The patent application was accepted by the Slovenian Intellectual Property Office (SIPO) on May 5 which was the priority date for the patent.
This has given MGC Pharma priority to file subsequent applications for CimetrA in other jurisdictions such as the European Union and the World Intellectual Property Organisation (WIPO).
CimetrA, previously known as ArtemiC, is an immune-modulation formula that is used to treat anti-inflammatory illnesses.
It is made up of artemisinin, a drug made from a fern-like plant that is used against malaria, and curcumin, a chemical that aids in anti-inflammatory and antioxidants.
It is then mixed with vitamin C and boswellia serrata, a herbal extract used to treat inflammatory illnesses.
MGC Pharma is now progressing towards its phase three clinical trial for CimetrA to demonstrate the full efficacy of the treatment in variants of COVID-19.
“We are delighted that the SIPO recognises the unique formulation of CimetrA, something we believe will be transformational in the treatment of COVID-19 as well as numerous other conditions,” Managing Director and Co-Founder Roby Zomer said.
“The submission of this patent application is an important next step in bringing CimetrA to market in multiple jurisdictions and ultimately treating people and patients on a global scale,” he added.
Shares in MGC Pharma are still down 11.3 per cent and are trading at 4.7 cents at 12:47 pm AEST.
